Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer
Recruiting · NCT06342284 · Observational (researchers observe without assigning treatment) · Lead sponsor: The New York Proton Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is an observational study involving the collection of patient-generated health data using an Apple Watch, a home pulse oximeter, and a smartphone during a course of proton beam radiotherapy for lung cancer. The study period over which this information is collected will range from the day of study enrollment until two weeks after radiotherapy completion. Subjects will complete a short satisfaction survey at the end of the study period. Other information that is collected as part of routine care for this patient population will be extracted from subjects' medical records during the study period and afterwards.
Who can take part
Inclusion criteria
- Plan for fractionated (≥15 treatments) proton beam thoracic radiotherapy with curative intent for lung cancer
- Non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) histology is permitted.
- Concurrent chemotherapy is permitted but not required..
- Previous thoracic radiotherapy is allowed.
- Ability to complete study surveys in English or Spanish
- Age \>/= 18
- Concurrent enrollment on other trials is permitted
- Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial, provided they agree to utilize the devices provided by the study team during the study period
- All patients must sign study-specific informed consent prior to study entry
Exclusion criteria
- Ongoing treatment for another cancer that is expected to affect the toxicity profile of thoracic radiotherapy
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
Where it is running
1 location listed across 1 US state.
- New York Proton Center - New York, New York, United States